Inovio Pharmaceuticals
211 hedge funds and large institutions have $682M invested in Inovio Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 68 increasing their positions, 46 reducing their positions, and 47 closing their positions.
48% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 46
0.04% less ownership
Funds ownership: 2.99% → 2.95% (-0.04%)
2% less capital invested
Capital invested by funds: $693M → $682M (-$11.3M)
9% less call options, than puts
Call options by funds: $33.9M | Put options by funds: $37.2M
3% less funds holding
Funds holding: 218 → 211 (-7)
13% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 47
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$14.9M |
| 2 |
D.E. Shaw & Co
New York
|
+$9.42M |
| 3 |
Goldman Sachs
New York
|
+$8.38M |
| 4 |
BlackRock
New York
|
+$5.26M |
| 5 |
State Street
Boston,
Massachusetts
|
+$5.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$37.2M |
| 2 |
Coatue Management
New York
|
-$29M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$7.28M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.33M |
| 5 |
California Public Employees Retirement System
Sacramento,
California
|
-$2.96M |
INO Hedge Fund Activity: Q2 2021 in Review
211 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q2 2021, worth a combined $682M — down 1.6% from $693M a quarter earlier.
Sellers outnumbered buyers: 47 funds closed out of INO and 41 opened new positions — a net loss of 6 holders — while 46 trimmed existing stakes and 68 added.
The largest buyer was JP Morgan Chase, adding an estimated $14.9M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $37.2M sold.
- 211 institutional investors held Inovio Pharmaceuticals (INO) as of Q2 2021, down from 218 in Q1 2021.
- Funds reported $682M of Inovio Pharmaceuticals stock for Q2 2021, down 1.6% quarter-over-quarter.
- 41 funds opened new Inovio Pharmaceuticals positions in Q2 2021 and 47 closed out, a net change of -6 holders.
- The largest Inovio Pharmaceuticals buyer in Q2 2021 was JP Morgan Chase, an estimated $14.9M added.
- The largest Inovio Pharmaceuticals seller in Q2 2021 was Avidity Partners Management, an estimated $37.2M sold.
Based on aggregated 13F filings for Q2 2021.